Pennsylvania contractor Clinlogix has bought Germany's ikfe CRO, looking to expand its presence in Europe's market for clinical development.
Clinlogix offers end-to-end services for medical device and biopharma clients, and with the ikfe buyout, the company is building on its existing European presence. With its continental headquarters in Germany, Clinlogix said the deal will bolster its offerings in diabetes, cardiovascular disease and oncology.
"This acquisition greatly strengthens our strategic resources, knowledge base and infrastructure in the largest pharmaceutical market in the world," Marco Grenningloh, managing director of Clinlogix Europe, said in a statement. "Ikfe CRO was a highly respected regional service provider, and their specialized expertise and in-depth understanding are further enhancing our ability to provide knowledgeable, high-quality services to our clients around the globe."
Since its foundation more than 20 years ago, the Spring House, PA-headquartered Clinlogix has expanded into the U.K, Germany and Latin America, covering the clinical development of medical devices, pharmaceuticals, biologics and diagnostics with services from discovery through first-in-human, pivotal and post-market studies.
- read the statement